|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||
| Current assets | ||||||||||||||||||
| Cash | ||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||
| Total Current assets | ||||||||||||||||||
| Interest-bearing Demand Deposit held in Trust Account | ||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' DEFICIT | ||||||||||||||||||
| Current liabilities | ||||||||||||||||||
| Accrued expenses | ||||||||||||||||||
| Promissory note - related party | ||||||||||||||||||
| Total Current liabilities | ||||||||||||||||||
| Warrant liabilities | ||||||||||||||||||
| Convertible promissory notes - related party, at fair value | ||||||||||||||||||
| Deferred underwriting fee | ||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||
| Class A ordinary shares subject to possible redemption; 3,076,094 shares at redemption value of approximately $12.48 and $12.33 per share as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||
| Class A Ordinary Shares Subject to Possible Redemption | ||||||||||||||||||
| SHAREHOLDERS' DEFICIT | ||||||||||||||||||
| Ordinary shares | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| TOTAL SHAREHOLDERS' DEFICIT | ||||||||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | ||||||||||||||||||
Loading...